QBiotics leadership update
BRISBANE: Friday, October 31, 2025
QBiotics Group Limited (QBiotics) today announces that Dr. Paul Reddell has concluded his employment with the Company. Dr. Reddell remains a Non-Executive Director on QBiotics’ Board. To ensure a smooth transition, Dr. Steven Ogbourne will assume expanded responsibilities, effective immediately.
Mr Mark Fladrich, QBiotics' Non-Executive Chairman commented, "The Board would like to acknowledge Paul’s long-standing contribution over the past 25 years as Co-founder and Chief Scientific Officer. We also thank Dr. Steve Ogbourne, whose extensive understanding of the Company and its operations will support the transition and continued focus on delivering QBiotics’ strategic priorities.”
Dr. Ogbourne has worked with QBiotics for nearly 15 years, currently serves as Chief Translational Research Officer, and a key member of the Leadership Team. Throughout his tenure, Dr. Ogbourne has also held a variety of other roles, including Non-Executive Director and Executive Director.
Appendix: Biographical information
Biography: Dr. Steven Ogbourne
Dr. Steven Ogbourne serves as Chief Translational Research Officer at QBiotics and holds an Adjunct Associate Professorship in Plant Biotechnology at University of the Sunshine Coast, where he has also held leadership roles, including Deputy Director of the Centre for BioInnovation. He previously served on the QBiotics Board for seven years (six as Non-Executive Director and one as Executive Director). Dr. Ogbourne’s prior appointments include NHMRC Industry Research Fellow at QIMR Berghofer and Senior Director of Research & Development at LEO Pharma.
With 25 years' experience in drug discovery and development focused on anticancer and dermatology assets, Dr. Ogbourne has made significant contributions across pharmacology, horticultural production, active pharmaceutical ingredient (API) manufacture, preclinical and clinical development, His work has included key advances in research on Fontainea picrosperma and the anti-cancer molecule, tigilanol tiglate. He holds a BSc (Honours) in Plant Science/Genetics and a PhD in Molecular Biology.
—ends—
FURTHER INFORMATION STEPHEN DOYLE, CEO & MANAGING DIRECTOR
or
MEDIA ENQUIRIES JANE LOWE, IR DEPARTMENT
jane.lowe@irdepartment.com.au or +61 411 117 774
NOTES FOR EDITORS
ABOUT QBIOTICS
QBiotics is an unlisted, public, Australian life sciences company that seamlessly connects scientific discovery, development and commercialisation to harness the power of nature to treat diseases of high unmet need.
Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds. We also have an early-stage antibiotics program.
QBiotics’ lead molecule, tigilanol tiglate, is a novel, small molecule with the potential to treat a broad range of solid tumours. It is currently in Phase II clinical trials in two indications: soft tissue sarcoma (STS) and head and neck cancer (HNC). Tigilanol tiglate was granted Orphan Drug Designation by the US FDA for the treatment of STS in February 2024.
A veterinary formulation of tigilanol tiglate (STELFONTA®) is approved for the treatment of canine mast cell tumours (MCTs), in major global markets, including the USA, Europe, and Australia. QBiotics has partnered with Virbac, a global animal health company, to distribute STELFONTA®.
Our wound healing drug candidate, EBC-1013, is a small molecule, which targets multiple pathways to accelerate healing, improving outcomes in chronic and acute wounds and burns. A first-in-human Phase I clinical trial in venous leg ulcers is open for recruitment.
For more, head to: QBiotics.com or LinkedIn